We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Sekisui XenoTech Adds Rodent, Monkey Hepatocytes to Patented CryostaX® Product Line

Sekisui XenoTech Adds Rodent, Monkey Hepatocytes to Patented CryostaX® Product Line content piece image
Credit: Sekisui XenoTech
Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Sekisui XenoTech’s CryostaX® in vitro drug discovery and preclinical drug development test systems now includes pooled Sprague-Dawley rat and CD-1 mouse hepatocytes. Cynomolgus monkey hepatocytes will also be added soon.

CryostaX® hepatocytes are prepared using a patented process that produces unique cryopreserved cell pellets. This single-freeze process:
• provides greater convenience, since there is no need to thaw the hepatocytes to get them out of the vial, which can potentially lead to ‘over-thawing’ and cell damage,
• versatile pooling options in lot sizes that can last for years,
• and minimizes cryopreservation freeze-thaw injury to the cells for high viability, cell yield and enzymatic activity for longer-term, consistent test results.

Data indicates benefits to CYP, SULT and UGT activity and extended culture up to 48 hours without a medium change. Eliminating the need for water baths in or near culture hoods and incubators also eliminates a significant source of contamination. Due to the clear superiority of CryostaX® products, the company foresees the potential discontinuation of cryopreserved hepatocytes prepared from traditional methods.